
    <!DOCTYPE html>
    <html>
    <head>
        <style>
            body { 
                font-family: 'Segoe UI', Roboto, -apple-system, sans-serif; 
                max-width: 1200px; 
                margin: 0 auto; 
                padding: 20px; 
                background-color: #f0f2f5;
                line-height: 1.6;
            }
            .container { 
                background-color: white; 
                padding: 40px; 
                border-radius: 16px; 
                box-shadow: 0 4px 12px rgba(0,0,0,0.1);
            }
            .agent-section { 
                margin-bottom: 35px; 
                padding: 25px; 
                border-radius: 12px; 
                transition: all 0.3s ease;
            }
            .agent-section:hover {
                transform: translateY(-2px);
                box-shadow: 0 4px 15px rgba(0,0,0,0.1);
            }
            .final-annotation { 
                background-color: #f0f7ff; 
                border-left: 5px solid #2196f3; 
            }
            .validator { 
                background-color: #f0fdf4; 
                border-left: 5px solid #22c55e; 
            }
            .formatting { 
                background: linear-gradient(145deg, #fff7ed, #ffe4c4);
                border-left: 5px solid #f97316; 
                box-shadow: 0 4px 15px rgba(249, 115, 22, 0.1);
            }
            h2 { 
                color: #1a2b3c; 
                margin-top: 0; 
                font-size: 1.5rem;
                font-weight: 600;
                display: flex;
                align-items: center;
                gap: 10px;
            }
            ul { 
                margin: 15px 0; 
                padding-left: 20px; 
            }
            pre { 
                background-color: #f8fafc; 
                padding: 20px; 
                border-radius: 8px; 
                overflow-x: auto;
                font-family: 'Consolas', 'Monaco', monospace;
                font-size: 0.9rem;
                line-height: 1.5;
            }
            .validation-result { 
                font-weight: 600; 
                color: #16a34a; 
                padding: 12px 20px;
                background-color: #dcfce7; 
                border-radius: 8px; 
                display: inline-block;
                margin: 10px 0;
            }
            br { 
                margin-bottom: 8px; 
            }
            p {
                margin: 12px 0;
                color: #374151;
            }
            .summary-content {
                display: flex;
                flex-direction: column;
                gap: 24px;
            }
            .summary-item {
                display: flex;
                flex-direction: column;
                gap: 8px;
                background: rgba(255, 255, 255, 0.7);
                padding: 16px;
                border-radius: 12px;
                backdrop-filter: blur(8px);
                box-shadow: 0 2px 8px rgba(0, 0, 0, 0.05);
            }
            .summary-label {
                font-weight: 600;
                color: #c2410c;
                font-size: 0.95rem;
                text-transform: uppercase;
                letter-spacing: 0.5px;
            }
            .summary-value {
                color: #1f2937;
                font-size: 1.1rem;
                padding: 8px 16px;
                background-color: rgba(255, 255, 255, 0.9);
                border-radius: 8px;
                display: inline-block;
                box-shadow: 0 1px 3px rgba(0, 0, 0, 0.1);
            }
            .summary-list {
                margin: 0;
                padding-left: 24px;
                list-style-type: none;
            }
            .summary-list li {
                color: #1f2937;
                padding: 8px 0;
                position: relative;
            }
            .summary-list li:before {
                content: "‚Ä¢";
                color: #f97316;
                font-weight: bold;
                position: absolute;
                left: -20px;
            }
            .report-header {
                text-align: center;
                margin-bottom: 40px;
                padding-bottom: 30px;
                border-bottom: 2px solid rgba(249, 115, 22, 0.2);
            }
            
            .report-title {
                font-size: 2.5rem;
                font-weight: 800;
                color: #1a2b3c;
                margin: 0;
                padding: 0;
                background: linear-gradient(135deg, #f97316, #c2410c);
                -webkit-background-clip: text;
                -webkit-text-fill-color: transparent;
                letter-spacing: -0.5px;
            }
            
            .report-subtitle {
                font-size: 1.1rem;
                color: #64748b;
                margin-top: 8px;
                font-weight: 500;
            }
            .scoring { 
                background: linear-gradient(145deg, #f0fdf4, #dcfce7);
                border-left: 5px solid #22c55e;
                box-shadow: 0 4px 15px rgba(34, 197, 94, 0.1);
            }
            .scoring-content {
                display: flex;
                flex-direction: column;
                gap: 16px;
                color: #1f2937;
                line-height: 1.8;
            }
            .scoring-content br + br {
                content: "";
                display: block;
                margin: 12px 0;
            }
            .empty-list {
                color: #6b7280;
                font-style: italic;
            }
            .error-message {
                color: #dc2626;
                padding: 12px;
                background-color: #fef2f2;
                border-radius: 6px;
                border-left: 4px solid #dc2626;
            }
            .score-badge {
                background: linear-gradient(135deg, #22c55e, #16a34a);
                color: white;
                padding: 8px 16px;
                border-radius: 12px;
                font-size: 1.5rem;
                font-weight: 700;
                display: inline-block;
                margin: 12px 0;
                box-shadow: 0 4px 12px rgba(34, 197, 94, 0.2);
                position: relative;
                top: -10px;
            }
            .score-badge::before {
                content: "Score:";
                font-size: 0.9rem;
                font-weight: 500;
                margin-right: 8px;
                opacity: 0.9;
            }
        </style>
    </head>
    <body>
        <div class="container">
            <div class="report-header">
                <h1 class="report-title">CASSIA Analysis Report</h1>
                <p class="report-subtitle">Comprehensive Cell Type Analysis and Annotation</p>
            </div>
            
                <div class="agent-section final-annotation">
                    <h2>üîç Final Annotation Analysis</h2>
                    ### Step-by-Step Analysis: #### **1. List the Key Functional Markers and Their Roles** The provided marker list is dominated by genes associated with **cell cycle progression, mitosis, and chromosomal segregation**. Here are the key functional groups: - **Mitotic spindle assembly & chromosome segregation**: - *HJURP* (Holliday junction recognition protein): Centromere assembly. - *CENPA* (Centromere protein A): Epigenetic marker of centromeres. - *KIF2C, KIF15, KIF18B* (Kinesin family members): Microtubule dynamics during mitosis. - *ASPM* (Abnormal spindle-like microcephaly-associated protein): Mitotic spindle organization. - *NUF2, SKA1, SKA3* (Kinetochore-microtubule attachment). - **Cell cycle regulation & DNA replication**: - *UBE2C* (Ubiquitin-conjugating enzyme E2 C): Anaphase-promoting complex (APC/C) regulator. - *AURKB* (Aurora kinase B): Chromosome alignment and cytokinesis. - *TOP2A* (Topoisomerase IIŒ±): Chromosome condensation/segregation. - *CDK1, CCNA2, CCNB2* (Cyclin-dependent kinases/cyclins): G2/M transition. - *MKI67* (Proliferation marker). - **DNA damage repair & replication**: - *RAD51AP1* (Homologous recombination). - *POLQ* (DNA polymerase theta, involved in alternative end-joining). - **Cytokinesis & cell division**: - *CEP55* (Centrosomal protein 55, midbody formation). - *PLK1* (Polo-like kinase 1, mitotic exit). #### **2. List the Key Cell Type Markers** The **absence of tissue-specific markers** (e.g., *EPCAM* for epithelial cells, *CD3D* for T cells, *CD68* for macrophages) suggests this cluster represents a **proliferating cell population** rather than a terminally differentiated cell type. #### **3. Cross-reference Known Databases** - **CellCycleScorer (Seurat)**: These markers are strongly associated with **G2/M phase**. - **Human Cell Atlas (HCA)**: Similar signatures are seen in **cycling epithelial progenitors** (e.g., intestinal crypt cells). - **PanglaoDB**: *MKI67+, TOP2A+, CDK1+* clusters are typically **proliferating cells** (e.g., stem/progenitor or transient amplifying cells). #### **4. Determine the Most Probable General Cell Type** Given the **exclusive enrichment of cell cycle-related genes** and **lack of differentiation markers**, this cluster is most likely: **‚Üí Cycling (proliferating) cells** #### **5. Identify the Top 3 Most Probable Sub Cell Types** Within the **intestinal epithelium**, the most likely candidates are: 1. **Transit-amplifying (TA) cells** (most likely): - Short-lived, rapidly dividing progenitors derived from stem cells. - Express *MKI67, TOP2A, CDK1* but lack mature lineage markers (e.g., *LGR5* for stem cells, *MUC2* for goblet cells). 2. **Intestinal stem cells (ISCs)**: - Less likely because *LGR5* (stem cell marker) is absent. - However, some ISCs may cycle and express *MKI67*. 3. **Immune proliferating cells (low probability)**: - Unlikely due to absence of *CD3E* (T cells), *CD79A* (B cells), or *CD68* (myeloid cells). **Final Subtype Annotation**: **‚Üí Transit-amplifying (TA) cells of the intestinal epithelium** #### **6. Concise Summary** - **Key markers**: Dominated by **cell cycle (G2/M phase) and mitotic regulators** (*TOP2A, MKI67, CDK1, AURKB*). - **Lack of differentiation markers**: Rules out mature epithelial/immune/stromal cells. - **Database alignment**: Matches **proliferating progenitors** in intestinal crypts. - **Most probable identity**: **Transit-amplifying (TA) cells** (cycling progenitors in the crypt). **FINAL ANNOTATION COMPLETED** --- **Final Answer**: **This cluster represents proliferating transit-amplifying (TA) cells of the intestinal epithelium, characterized by strong G2/M-phase cell cycle activity.** *(Note: If additional markers like LGR5 or differentiation genes were present, the annotation could be refined further.)*
                </div>
            
                <div class="agent-section validator">
                    <h2>‚úì Validation Check</h2>
                    <div class="validation-result">‚úÖ VALIDATION PASSED</div>
                    Validation result: VALIDATION PASSED ### Feedback: 1. **Marker Consistency**: - The annotation **'proliferating transit-amplifying (TA) cells of the intestinal epithelium'** is strongly supported by the provided markers, which are overwhelmingly associated with **cell cycle progression (G2/M phase)** and mitosis (*TOP2A, MKI67, CDK1, AURKB, PLK1, CCNB2*). - The absence of lineage-specific markers (*LGR5, MUC2, CD3D, CD68*, etc.) rules out mature/differentiated cell types, aligning with the TA cell hypothesis. 2. **Mixed Cell Type Consideration**: - No evidence of mixed populations. All top markers coherently point to a **proliferating progenitor-like state**. 3. **Database Alignment**: - Matches known signatures of **intestinal crypt TA cells** (e.g., *MKI67+*, *TOP2A+*, *CDK1+* but *LGR5‚Äì*) in references like PanglaoDB and HCA. **Suggested Refinement (Optional)**: - If spatial transcriptomics or additional markers (e.g., *LGR5*, *OLFM4*) become available, further distinction between **TA cells vs. cycling stem cells** could be explored. **Final Verdict**: The annotation is biologically plausible and well-supported by the data.
                </div>
            
                    <div class="agent-section formatting">
                        <h2>üìã Summary</h2>
                        <p class="error-message">Error formatting data: Expecting property name enclosed in double quotes: line 1 column 3 (char 2)</p>
                    </div>
                
                    <div class="agent-section scoring">
                        <h2>üéØ Quality Assessment</h2>
                        <div class="score-badge">95</div>
                        <div class="scoring-content">
                            The annotation results demonstrate a strong and scientifically accurate interpretation of the provided markers, aligning well with known biological functions and cell type signatures. Here‚Äôs a detailed evaluation:<br><br>### **Strengths**:<br>1. **Correctness of Annotations**:<br>   - The annotation as **proliferating transit-amplifying (TA) cells** is highly plausible given the dominance of cell cycle and mitosis-related markers (*TOP2A, MKI67, CDK1, AURKB, PLK1*). These genes are hallmark features of cycling cells, particularly in the G2/M phase, which is consistent with TA cells in the intestinal epithelium.<br>   - The exclusion of terminally differentiated cell types (e.g., goblet cells, immune cells) due to the absence of lineage-specific markers (*LGR5, MUC2, CD3D, CD68*) is logically sound.<br><br>2. **Balanced Marker Consideration**:<br>   - The analysis does not overemphasize a single marker but instead integrates a broad spectrum of functionally related genes (e.g., kinesins like *KIF2C*, *KIF15*; cyclins like *CCNB2*; and chromosomal regulators like *CENPA*). This holistic approach strengthens the annotation‚Äôs reliability.<br>   - The use of databases (CellCycleScorer, HCA, PanglaoDB) to cross-validate the markers adds robustness to the conclusion.<br><br>3. **Comprehensive View of Cell Populations**:<br>   - The annotation captures the general picture of a **proliferating progenitor population** without overclaiming specificity (e.g., acknowledging the low probability of immune proliferating cells due to missing markers).<br>   - The consideration of sub-cell types (TA cells, ISCs) reflects a nuanced understanding of intestinal epithelial hierarchy.<br><br>4. **Rank Awareness**:<br>   - While the analysis doesn‚Äôt explicitly rank markers by expression level, the functional grouping (e.g., prioritizing *HJURP*, *CENPA* for centromere assembly and *CDK1*, *CCNB2* for cell cycle) implicitly reflects biological relevance.<br><br>### **Weaknesses**:<br>1. **Lack of Spatial or Lineage Context**:<br>   - The annotation could be further refined with spatial transcriptomics or additional markers (e.g., *LGR5* for stem cells, *OLFM4* for crypt base columnar cells) to distinguish TA cells from cycling stem cells. This is noted as a suggestion but not explored in depth.<br><br>2. **Overlap with Other Proliferating Cells**:<br>   - While unlikely, the analysis could briefly address why this signature isn‚Äôt from a rare proliferating stromal or immune population (e.g., by explicitly stating the absence of *VIM* or *PECAM1*).<br><br>### **Minor Oversights**:<br>- The marker *DIAPH3* (involved in cytokinesis) isn‚Äôt discussed, though it fits the mitotic theme. This doesn‚Äôt detract from the overall correctness but highlights a minor gap in marker coverage.<br><br>### **Final Assessment**:<br>The annotation is **highly accurate**, leveraging a comprehensive marker set to infer a biologically coherent cell type. The minor limitations (contextual refinement, rare cell type exclusion) do not undermine the core conclusion.<br>
                        </div>
                    </div>
                
        </div>
    </body>
    </html>
    